|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007113,
umls-concept:C0021149,
umls-concept:C0080103,
umls-concept:C0544886,
umls-concept:C0600558,
umls-concept:C0871261,
umls-concept:C0936012,
umls-concept:C1559154,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-5-27
|
|
pubmed:abstractText |
The identification of predictive markers of response to chemoradiotherapy treatment remains a promising approach for patient management in order to obtain the best response with minor side effects. Initially, we investigated whether the analysis of several markers previously studied and others not yet evaluated could predict response to 5-fluorouracil- and capecitabine-based neoadjuvant treatment in locally advanced rectal cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1744-8042
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
747-61
|
|
pubmed:meshHeading |
pubmed-meshheading:20504250-Adult,
pubmed-meshheading:20504250-Aged,
pubmed-meshheading:20504250-Aged, 80 and over,
pubmed-meshheading:20504250-Antimetabolites, Antineoplastic,
pubmed-meshheading:20504250-Chemotherapy, Adjuvant,
pubmed-meshheading:20504250-DNA,
pubmed-meshheading:20504250-Deoxycytidine,
pubmed-meshheading:20504250-Female,
pubmed-meshheading:20504250-Fluorouracil,
pubmed-meshheading:20504250-Genotype,
pubmed-meshheading:20504250-Humans,
pubmed-meshheading:20504250-Logistic Models,
pubmed-meshheading:20504250-Male,
pubmed-meshheading:20504250-Middle Aged,
pubmed-meshheading:20504250-Multivariate Analysis,
pubmed-meshheading:20504250-Mutation,
pubmed-meshheading:20504250-Neoadjuvant Therapy,
pubmed-meshheading:20504250-Neoplasm Staging,
pubmed-meshheading:20504250-Pharmacogenetics,
pubmed-meshheading:20504250-Polymerase Chain Reaction,
pubmed-meshheading:20504250-Polymorphism, Genetic,
pubmed-meshheading:20504250-Predictive Value of Tests,
pubmed-meshheading:20504250-Radiotherapy, Adjuvant,
pubmed-meshheading:20504250-Rectal Neoplasms,
pubmed-meshheading:20504250-Thymidylate Synthase,
pubmed-meshheading:20504250-Treatment Outcome,
pubmed-meshheading:20504250-Tumor Markers, Biological
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
|
|
pubmed:affiliation |
Grupo Medicina Xenomica-CIBERER, Fundación Publica Galega de Medicina Xenómica, Santiago de Compostela, Spain. emilia.balboa@usc.es
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
